growth - The 18.5% revenue growth, biosimilar pipeline expansion, and negative FCF profile attract growth investors willing to accept…
Rising interest rates create moderate headwinds through higher financing costs on the 0.79x debt/equity ratio and pressure valuation…
Watch on earnings: Korean won (KRW) exchange rate versus USD - impacts imported raw materials and plasma procurement costs, Korean healthcare expenditure as % of GDP - indicates government commitment to reimbursement levels, Global immunoglobulin pricing trends - plasma therapeutics represent 35-40% of revenue.
One Sentence Summary:
GC: the story is balanced — biosimilar approval milestones and market share capture in key therapeutic areas (oncology, immunology).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
